Teclistamab (BCMA×CD3 bispecific) drives 76.9% ORR and 25.1-mo mPFS in TCE-RRMM (China)

Teclistamab is a subcutaneous BCMA×CD3 T-cell–redirecting bispecific antibody evaluated in the MajesTEC-1 China cohort with 27.2 months’ follow-up in triple-class exposed RRMM (n=26), dosed 1.5mg/kg weekly with an option to transition to every-2-week dosing in sustained responders (NCT03145181/NCT04557098). ORR was 76.9%, with 100% of responders reaching ≥VGPR and 75% reaching ≥CR; median PFS was 25.1 months, while median DOR and OS were not reached, and among ≥CR patients the estimated 30-month DOR/PFS/OS rates were 80.0%/80.0%/93.3%. These outcomes appear well above historical late-line non–T-cell–redirecting “salvage” benchmarks (e.g., selinexor+dexamethasone ORR ~26%, mPFS 3.7 months; belantamab mafodotin ORR ~31% with short mPFS ~2.8 months), and even exceed the broader MajesTEC-1 dataset at earlier follow-up (ORR 63% with 39.4% ≥CR), though cross-trial comparisons are inherently confounded by differing populations and follow-up; safety was stated as consistent with prior reports, with new-onset Grade ≥3 infections decreasing over time (potentially coincident with Q2W dosing and immunoglobulin use) and QoL improving across multiple domains.